Regeneron Pharmaceuticals

Milestones as listed on regeneron.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on regeneron.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on regeneron.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on regeneron.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Regeneron Pharmaceuticals: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 6 Oct 2026.

Clinical trials 104 in our ClinicalTrials.gov registers · 17 in the EU register

Showing 10 of 104, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 64 compounds

EU trials register (CTIS) 17 authorised or ongoing

• REGN9220 in Combination with Odronextamab in Adult Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)2025-524780-20-00 · Phase I · Authorised
• First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis2025-524205-32-00 · Phase I · Ongoing
• A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living with Overweight or Obesity without Diabetes (RISE-1)2025-524861-26-00 · Phase III · Authorised
• A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)2025-521617-97-00 · Phase III · Authorised
• A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)2025-521618-25-00 · Phase III · Authorised
• A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)2025-522954-37-00 · Phase III · Authorised
• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)2024-519298-21-00 · Phase III · Authorised
• Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation2026-525464-18-00 · Phase I · Ongoing

NICE technology appraisals 16 of its medicines · 16 current

• Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapyNICE TA1174 · Optimised · 9 Jul 2026
• Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerNICE TA1165 · Optimised · 16 Jun 2026
• Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsNICE TA1142 · Optimised · 26 Mar 2026
• Dupilumab for treating severe chronic rhinosinusitis with nasal polypsNICE TA1134 · Optimised · 18 Feb 2026
• Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and overNICE TA1002 · Recommended · 11 Sep 2024
• Dupilumab for treating moderate to severe prurigo nodularisNICE TA955 · Not recommended · 13 Mar 2024
• Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)NICE TA938 · Terminated (no company submission) · 7 Dec 2023
• Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)NICE TA848 · Terminated (no company submission) · 1 Dec 2022

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Regeneron Pharmaceuticals): founded 1988, headquarters Eastview, website regeneron.com. Wikidata Q7308054 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Regeneron Pharmaceuticals; Regeneron Pharmaceuticals Inc.; Regeneron Ireland U.C.; Regeneron Ireland Designated Activity Company; REGENERON PHARMACEUTICALS; Regeneron Ireland Designated Activity Company (DAC). Spot a wrong match? Tell us.

From the annual reports Regeneron Pharmaceuticals, Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 1 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Regeneron Pharmaceuticals, Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.